Top 3 Australian Growth Stocks To Watch In September 2026

Rising bond yields are pulling attention toward safer income assets, which means investors willing to stay in equities are demanding clearer growth stories and solid balance sheets. That is exactly where a basket of financially healthy, high potential Australian growth stocks can help. This article breaks down three standouts from that group so you can see which traits analysts are focusing on in the coming years.

The three stocks highlighted below are just a sample, with the wider screen surfacing 93 more companies that share similarly compelling growth and balance sheet stories that are not covered in this article.

If you want to quickly identify and analyze the ones that best fit your own criteria, head straight to the Healthy high growth potential screener.

Overview: 4DMedical develops non invasive respiratory imaging software and scanners such as CT:VQ and XV Scanner that quantify lung function for clinicians.

Operations: The business generates about A$7.1 million from medical technology R & D of lung function analysis, mostly in the United States with a smaller Australian contribution.

Market Cap: A$2.4b

4DMedical fits the Healthy high growth potential theme through its focus on software driven lung imaging tools that can scale with hospital and clinic adoption. This gives earnings forecasts something concrete to rest on rather than a purely conceptual story.

“Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America.”

What happens to 4DMedical’s long term earnings profile depends on how one unseen pressure shapes demand and pricing power from here.

That pressure is exactly what the full narrative for 4DMedical unpacks in detail, highlighting how Philips demand, capital needs and pricing power could be quietly reshaping 4DMedical’s trajectory.

Overview: Neuren Pharmaceuticals develops and commercializes treatments for neurological disorders, led by DAYBUE for Rett syndrome and the NNZ-2591 pipeline.

Operations: Neuren generates about A$69.5 million from commercial products, with all reported revenue currently coming from the United States market.

Market Cap: A$2.6b

Neuren Pharmaceuticals fits the Healthy high growth potential theme because of DAYBUE’s commercial rollout and the advancing NNZ-2591 programs, which together give analysts concrete products and late stage trials to include in their earnings and revenue models.

“Planned expansion into international markets, such as Canada, Europe, and Japan, offers significant long-term growth prospects and additional revenue streams due to higher royalty rates outside the U.S.”

What really decides how powerful that growth becomes is whether one less visible constraint quietly tightens or loosens around future profitability.

That profitability choke point is exactly what the full narrative for Neuren Pharmaceuticals unpacks, showing how Neuren Pharmaceuticals could see DAYBUE royalties accelerate while pipeline risks are managed in plain sight.

Overview: Megaport runs a Software Defined Network platform that lets enterprises buy on-demand, subscription-based cloud and data center connectivity worldwide.

Operations: The business generates about A$312.2 million in revenue, with A$198 million from the Americas, A$70 million from Asia Pacific, and A$44 million from Europe.

Market Cap: A$4.6b

Megaport fits the Healthy high growth potential theme through its SDN and cloud interconnect platform, where recurring connectivity subscriptions are the main engine behind analysts’ earnings growth expectations and rely on a balance sheet that is being actively managed through recent capital raises.

“Skyrocketing enterprise bandwidth, surging AI/cloud adoption, and the rapid proliferation of data centers are combining to create secular tailwinds. Megaport’s automation, global reach, and software-defined architecture give it the potential to be the connectivity backbone for AI factories, data-native SaaS, and hybrid enterprise networks.”

What ultimately shapes how that growth translates into lasting shareholder value is how one unresolved funding and profitability tension gets resolved.

That funding trade off is exactly what the full narrative for Megaport breaks down, separating hype from where Megaport’s earnings power could be quietly accelerating next.

Seeking Fresh Alternatives Before They Fly

Fresh ideas tend to move early and move quickly. Breakout stories can gain momentum while they are still under the radar for now. Consider researching sooner rather than later instead of reacting after the fact.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com